Veliparib information

Veliparib
Clinical data
ATC code	L01XK05 (WHO) ;
Identifiers
	IUPAC name 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide;
CAS Number	912444-00-9 ;
PubChem CID	11960529;
IUPHAR/BPS	7417;
DrugBank	DB07232 ;
ChemSpider	10134775 ;
UNII	01O4K0631N;
KEGG	D09692;
ChEMBL	ChEMBL506871 ;
CompTox Dashboard (EPA)	DTXSID90238456 ;
ECHA InfoCard	100.206.770
Chemical and physical data
Formula	C13H16N4O
Molar mass	244.298 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]3(c2nc1c(C(N)=O)cccc1[nH]2)CCCN3;
	InChI InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)/t13-/m1/s1 ; Key:JNAHVYVRKWKWKQ-CYBMUJFWSA-N ;
	(what is this?) (verify)

Veliparib (ABT-888)^[1] is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.^[2]

It inhibits both PARP1 and PARP2^[1] and thereby induces synthetic lethality.It is still being evaluated for the treatment of ovarian cancer.^[3]

^ ^a ^b Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. (May 2007). "ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models". Clinical Cancer Research. 13 (9): 2728–2737. doi:10.1158/1078-0432.CCR-06-3039. PMID 17473206. S2CID 15532443.
^ Cite error: The named reference adis was invoked but never defined (see the help page).
^ Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, et al. (February 2020). "Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach". Investigational New Drugs. 38 (1): 181–193. doi:10.1007/s10637-019-00867-4. PMID 31650446. S2CID 204882729.

[Donawho_2007-1] Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. (May 2007). "ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models". Clinical Cancer Research. 13 (9): 2728–2737. doi:10.1158/1078-0432.CCR-06-3039. PMID 17473206. S2CID 15532443.

[adis-2] Cite error: The named reference adis was invoked but never defined (see the help page).

[Boussios_2020-3] Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, et al. (February 2020). "Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach". Investigational New Drugs. 38 (1): 181–193. doi:10.1007/s10637-019-00867-4. PMID 31650446. S2CID 204882729.

Veliparib information

and 29 Related for: Veliparib information

Veliparib

PARP inhibitor

Methotrexate

Tretinoin

Cancer immunotherapy

Venetoclax

Lifileucel

Abemaciclib

Celecoxib

Hydroxycarbamide

Carboplatin

FOLFIRI

Etoposide

Paclitaxel

List of antineoplastic agents

Drug nomenclature

Temozolomide

Photodynamic therapy

Cisplatin

Nelarabine

Idecabtagene vicleucel

Sotorasib

Nocodazole

Nitrogen mustard

Olaparib

Docetaxel

Cyclophosphamide

Doxorubicin

Azacitidine

Clinical data

ATC code	L01XK05 (WHO)
Identifiers
IUPAC name 2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
CAS Number	912444-00-9^Y
PubChem CID	11960529
IUPHAR/BPS	7417
DrugBank	DB07232^N
ChemSpider	10134775^N
UNII	01O4K0631N
KEGG	D09692
ChEMBL	ChEMBL506871^N
CompTox Dashboard (EPA)	DTXSID90238456
ECHA InfoCard	100.206.770
Chemical and physical data
Formula	C₁₃H₁₆N₄O
Molar mass	244.298 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C[C@]3(c2nc1c(C(N)=O)cccc1[nH]2)CCCN3
InChI InChI=1S/C13H16N4O/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17)/t13-/m1/s1^N Key:JNAHVYVRKWKWKQ-CYBMUJFWSA-N^N
^NY (what is this?) (verify)